Irbesartan/Hydrochlorothiazide Teva

Irbesartan, the active ingredient in Irbesartan/Hydrochlorothiazide Teva, is an angiotensin II receptor blocker presented as a tablet for oral use. It is combined with hydrochlorothiazide, a thiazide diuretic, to treat hypertension in adult patients.

GNH USA supplies Irbesartan/Hydrochlorothiazide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable logistics for global distribution.

Irbesartan/Hydrochlorothiazide is indicated for the management of hypertension, acting on the renin‑angiotensin system and fluid balance. - Essential hypertension: lowers systolic and diastolic blood pressure to target levels. - Stage 1 or 2 high blood pressure: provides effective blood‑pressure control when monotherapy is insufficient. - Combination therapy for elevated blood pressure: offers dual action through vasodilation and diuresis for patients requiring more than one antihypertensive agent.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury or worsening renal function - Hypotension (significant drop in blood pressure) - Allergic reactions such as rash, angioedema, or anaphylaxis - Elevated blood urea nitrogen or creatinine levels - Rare cases of pancreatitis or hepatic dysfunction

Before initiating therapy, consider the following precautions: - Renal function monitoring: assess serum creatinine and electrolytes regularly. - Electrolyte balance: watch for hypokalemia, especially when combined with other diuretics. - Elderly patients: start at lower doses and monitor for orthostatic hypotension. - Concomitant use with other antihypertensives: adjust dose to avoid excessive blood‑pressure reduction. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines. Major Interactions (Avoid): - Aliskiren in patients with diabetes or renal impairment: risk of hyperkalemia and renal dysfunction. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: increased lithium levels leading to toxicity. - NSAIDs (e.g., ibuprofen, naproxen): can reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - ACE inhibitors or other ARBs: additive effect on potassium and renal function. - Other antihypertensives (beta‑blockers, calcium channel blockers): may require dose adjustments. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase irbesartan plasma concentrations. - Antidiabetic agents: diuretic‑induced changes in glucose may affect glycemic control.